Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial.

被引：0
|
作者：
Meng, Xiangrui
Yang, Xiuli
Hong, Yong-Gui
Zhang, Zhiye
Xia, Jin
Chen, Yunfang
Wu, Tao
Shan, Zheng-Zheng
Fan, Qingxia
Wang, Feng
机构：
[1] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
[2] First Affiliated Hosp, Nanyang Med Coll, Nanyang, Peoples R China
[3] Anyang Tumor Hosp, Anyang, Henan, Peoples R China
[4] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Med Oncol, Luoyang, Peoples R China
[5] Zhumadian Cent Hosp, Zhumadian, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16035
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Anlotinib plus TQB2450, a PD-L1 Antibody, in Patients with Advanced Alveolar Soft Part Sarcoma: A Single-Arm, Phase II Trial
    Tan, Zhichao
    Wu, Yan
    Fan, Zhengfu
    Gao, Tian
    Guo, Wei
    Bai, Chujie
    Xue, Ruifeng
    Li, Shu
    Zhang, Lu
    Wang, Xinyu
    Jia, Ling
    Liu, Jiayong
    CLINICAL CANCER RESEARCH, 2024, 30 (24) : 5577 - 5583
  • [22] Benmelstobart (TQB2450) alone or combined with anlotinib in previously treated advanced endometrial cancer: updated results from a multicohort, open-label, multicenter phase II clinical trial TQB2450-II-08
    Wu, Xiaohua
    Chen, Xiaojun
    Luo, Xuezhen
    Wang, Ke
    Wang, Dong
    An, Ruifang
    Hou, Jianqing
    Yang, Ying
    Wang, Danbo
    Qu, Pengpeng
    Zhang, Bingzhong
    Duan, Wei
    Li, Xiumin
    Zang, Aimin
    Yu, Guohua
    Lou, Hanmei
    Yao, Desheng
    Wang, Shuzhen
    Yan, Dong
    Li, Liang
    Liu, Xiaowei
    Zhao, Weidong
    Chen, Zhengzheng
    Fei, Jing
    Li, Jundong
    Wang, Jing
    Wang, Zhilian
    Yao, Shuzhong
    Ning, Fangling
    Zhou, Huaijun
    Sun, Li
    Pan, Lingya
    Liu, Qing
    Yang, Haihua
    Wang, Li
    Zhang, Mingjun
    Chen, Xiaoxiang
    Yuan, Jianlin
    Zhang, Xinwen
    Zhang, Youzhong
    Liao, Qinping
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A6 - A6
  • [23] Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II trial.
    Chen, Yueyun
    Ding, Zhen-Yu
    Yuan, Yong
    Yang, Yu-Shang
    Lin, Zhen
    Tian, Jiangfang
    Liu, Ting
    Yue, Zheng
    Shi, Hua-Shan
    Hu, Yang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 352 - 352
  • [24] TQB2450 injection combined with anlotinib hydrochloride capsule in the treatment of advanced, recurrent or metastatic endometrial cancer: A multicohort, open label, multicenter phase II clinical trial - The TQB2450-II-08 trial
    Wu, X.
    Liang, S.
    Chen, X.
    Hou, J.
    Wang, K.
    Wang, D.
    An, R.
    Zang, A.
    Li, X.
    Zhang, B.
    Qu, P.
    Duan, W.
    Yu, G.
    Wang, D.
    Yan, D.
    Wang, J.
    Yao, D.
    Wang, S.
    Zhao, W.
    Lou, H.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S802 - S802
  • [25] Benmelstobart (TQB2450) combined with anlotinib hydrochloride capsule in the treatment of advanced, recurrent, or metastatic endometrial cancer: A multicohort, open label, multicenter, phase II clinical trial (TQB2450-II-08)
    Wu, Xiaohua
    Chen, Xiaojun
    Wang, Ke
    Wang, Dong
    An, Ruifang
    Hou, Jianqing
    Yang, Ying
    Wang, Danbo
    Qu, Pengpeng
    Zhang, Bingzhong
    Duan, Wei
    Li, Xiumin
    Zang, Ai-Min
    Yu, Guohua
    Lou, Hanmei
    Yao, Desheng
    Wang, Shuzhen
    Yan, Dong
    Li, Liang
    Liu, Xiaowei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment (NAT) for esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, phase. clinical trial.
    Zhang, Yan-Feng
    Li, Xiao-Bing
    Hong, Yong-Gui
    Li, Xiao-Ming
    Liang, Wei-Min
    Zheng, Zhi-Xin
    Yang, Guang-Yi
    Wen, Yan-Yan
    Cao, Heng
    Wu, Wei-Long
    Su, Wen-Zhong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 366 - 366
  • [27] Fruquintinib plus camrelizumab combined with paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II clinical trial
    Qiu, Tianzhu
    Mingjie, Lu
    Dong, Yuwen
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 445 - 445
  • [28] Anlotinib in combined with anti-PD-L1 antibody Benmelstobart(TQB2450) versus sunitinib in first-line treatment of advanced renal cell carcinoma (RCC): A randomized, open-label, phase III study (ETER100)
    Sheng, X.
    Shen, P.
    Qu, W.
    Wang, Z.
    Li, Y.
    Ren, X.
    Jiang, S.
    Li, G.
    Fu, C.
    Qin, W.
    Wu, J.
    Chen, P.
    Guo, H.
    Zhou, F.
    Ji, Z.
    Yang, A.
    Chen, K.
    Li, L.
    Zhou, A.
    Guo, J.
    ANNALS OF ONCOLOGY, 2024, 35 : 1263 - 1264
  • [29] TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study
    Huang, Z.
    Zhou, J.
    Yang, M.
    Zhang, W.
    Sun, Y.
    Lu, H.
    Wang, H.
    Bi, X.
    Zhang, Y.
    Zhao, J.
    Yang, Y.
    Zhang, B.
    Ye, F.
    Zhao, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S1545 - S1545
  • [30] Tislelizumab in combination with anlotinib as first-line treatment for unresectable hepatocellular carcinoma: A single-arm, phase II clinical trial.
    Laoguo, Shi-xue
    Huang, Huasheng
    Zeng, Jie
    Jiang, Yangfeng
    Liu, Cuizhen
    Mo, Ning
    Zhu, GuangZhi
    Ma, Fuchao
    Peng, Tao
    Zeng, Zhiming
    Ma, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 576 - 576
12345